SCHEMBL5134872

SCHEMBL5134872

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(OC)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 4/20 0.43
TSHR P16473 4/20 0.43
POLB P06746 1/20 0.43
BCHE P06276 3/20 0.37
GAA P10253 4/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136562 0.97 ALDH1A1 (0.46) C5AR1ALDH1A1KDM4ETSHRPOLB
SCHEMBL5136856 0.94 C5AR1 (0.45) C5AR1ALDH1A1KDM4ETSHRBCHE
SCHEMBL5134673 0.93 C5AR1 (0.43) C5AR1ALDH1A1KDM4ETSHRBCHE
SCHEMBL5136651 0.91 C5AR1 (0.43) C5AR1ALDH1A1KDM4ETSHRPOLB
SCHEMBL5137111 0.91 ALDH1A1 (0.42) C5AR1ALDH1A1KDM4ETSHRPOLB
SCHEMBL5134702 0.91 ALDH1A1 (0.42) C5AR1ALDH1A1KDM4ETSHRPOLB
SCHEMBL651365 0.91 C5AR1 (0.46) C5AR1ALDH1A1KDM4ETSHRBCHE
SCHEMBL5135495 0.90 C5AR1 (0.43) C5AR1ALDH1A1KDM4ETSHRBCHE
SCHEMBL5072205 0.90 C5AR1 (0.46) C5AR1ALDH1A1KDM4ETSHRBCHE
SCHEMBL5135242 0.89 C5AR1 (0.45) C5AR1ALDH1A1KDM4ETSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed